TY - JOUR
T1 - Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid
T2 - a systematic review
AU - van Westrhenen, Anouk
AU - Smidt, Lisanne C.A.
AU - Seute, Tatjana
AU - Nierkens, Stefan
AU - Stork, Abraham C.J.
AU - Minnema, Monique C.
AU - Snijders, Tom J.
N1 - Publisher Copyright:
© 2018 The Authors. British Journal of Haematology published by John Wiley & Sons Ltd and British Society for Haematology.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2018/8
Y1 - 2018/8
N2 - Diagnosing central nervous system (CNS) lymphoma remains a challenge. Most patients have to undergo brain biopsy to obtain tissue for diagnosis, with associated risks of serious complications. Diagnostic markers in blood or cerebrospinal fluid (CSF) could facilitate early diagnosis with low complication rates. We performed a systematic literature search for studies on markers in blood or cerebrospinal fluid for the diagnosis CNS lymphoma and assessed the methodological quality of studies with the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2). We evaluated diagnostic value of the markers at a given threshold, as well as differences between mean or median levels in patients versus control groups. Twenty-five studies were included, reporting diagnostic value for 18 markers in CSF (microRNAs -21, -19b, and -92a, RNU2-1f, CXCL13, interleukins -6, -8, and -10, soluble interleukin-2-receptor, soluble CD19, soluble CD27, tumour necrosis factor-alfa, beta-2-microglobulin, antithrombin III, soluble transmembrane activator and calcium modulator and cyclophilin ligand interactor, soluble B cell maturation antigen, neopterin and osteopontin) and three markers in blood (microRNA-21 soluble CD27, and beta-2-microglobulin). All studies were at considerable risk of bias and there were concerns regarding the applicability of 15 studies. CXCL-13, beta-2-microglobulin and neopterin have the highest potential in diagnosing CNS lymphoma, but further study is still needed before they can be used in clinical practice.
AB - Diagnosing central nervous system (CNS) lymphoma remains a challenge. Most patients have to undergo brain biopsy to obtain tissue for diagnosis, with associated risks of serious complications. Diagnostic markers in blood or cerebrospinal fluid (CSF) could facilitate early diagnosis with low complication rates. We performed a systematic literature search for studies on markers in blood or cerebrospinal fluid for the diagnosis CNS lymphoma and assessed the methodological quality of studies with the Quality Assessment of Diagnostic Accuracy Studies tool (QUADAS-2). We evaluated diagnostic value of the markers at a given threshold, as well as differences between mean or median levels in patients versus control groups. Twenty-five studies were included, reporting diagnostic value for 18 markers in CSF (microRNAs -21, -19b, and -92a, RNU2-1f, CXCL13, interleukins -6, -8, and -10, soluble interleukin-2-receptor, soluble CD19, soluble CD27, tumour necrosis factor-alfa, beta-2-microglobulin, antithrombin III, soluble transmembrane activator and calcium modulator and cyclophilin ligand interactor, soluble B cell maturation antigen, neopterin and osteopontin) and three markers in blood (microRNA-21 soluble CD27, and beta-2-microglobulin). All studies were at considerable risk of bias and there were concerns regarding the applicability of 15 studies. CXCL-13, beta-2-microglobulin and neopterin have the highest potential in diagnosing CNS lymphoma, but further study is still needed before they can be used in clinical practice.
KW - blood
KW - central nervous system (CNS) lymphoma
KW - cerebrospinal fluid (CSF)
KW - diagnostic marker(s)
KW - liquid biopsy
UR - http://www.scopus.com/inward/record.url?scp=85047273538&partnerID=8YFLogxK
U2 - 10.1111/bjh.15410
DO - 10.1111/bjh.15410
M3 - Article
C2 - 29808930
AN - SCOPUS:85047273538
SN - 0007-1048
VL - 182
SP - 384
EP - 403
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 3
ER -